Physician profile
John Untisz
NPI 1932430360
$1,735.25
in general payments reported to CMS, 2019-2025
14 companies · $95.94 in 2025
The $95.94 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $99.99 · 2020: $139 · 2022: $200 · 2023: $73.69 · 2024: $1,127 · 2025: $95.94.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $941 · Food and Beverage: $355.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $941.04 |
| Food and Beverage | $355.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Olympus Corporation of The Americas | $1,001.04 | 2024-2025 | |
| Olympus America INC. | $153.67 | 2024 | Spiration Valve System |
| Astrazeneca Pharmaceuticals LP | $136.78 | 2020-2022 | |
| Steris Corporation | $117.46 | 2022 | |
| Genentech USA, INC. | $99.99 | 2019 | |
| Merck Sharp & Dohme LLC | $50.14 | 2022-2023 | Verquvo |
| Electromed, INC. | $32.40 | 2024-2025 | Smartvest |
| Amgen INC. | $30.33 | 2022-2023 | Tezspire |
| Acacia Pharma INC | $24.31 | 2022 | |
| Pfizer INC. | $22.39 | 2023 | |
| Breas Medical, INC. | $19.36 | 2025 | Vivo 45 Ls |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.17 | 2022 | |
| Mylan Pharmaceuticals INC. | $16.00 | 2024 | Yupelri |
| Chiesi USA, INC. | $14.21 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Untisz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.